Isabella C. Glitza Oliva, MD, PhD, MS, an assistant professor within the Department of Melanoma Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the prognosis of patients with melanoma brain and/or central nervous system (CNS) metastases.
Video Reports
Dr. Luke on Future Research With T-Cell Therapy in Melanoma
Jason J. Luke, MD, FACP, associate professor of medicine, Division of Hematology/Oncology, and director of the Cancer Immunotherapeutics Center Immunology and Immunotherapy Program, University of Pittsburgh Medical Center Hillman Cancer Center, discusses the future of T-cell therapy in melanoma.
Advances in the Treatment of Malignant Melanoma
Jeffrey S. Weber, MD, PhD: Hello, and welcome to this OncLive® Peer Exchange® titled “Advances in the Treatment of Malignant Melanoma.”
Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma
Axel Hauschild, MD, PhD, a professor of dermatology at the University Hospital Schleswig-Holstein, in Campus Kiel, Germany, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.